TABLE 1

Patient Demographics, Response, and Survival

						Dose administered		Response		Survival
Patient no.	Age at treatment (y)	MYCN status	No. of prior relapses	Prestudy status	Prestudy ¹²³I-MIBG score	Actual ¹³¹I-MIBG (MBq/kg)	Arsenic trioxide (mg/kg/d)	INRC	Relative ¹³¹I-MIBG score	Progression-free survival (mo)	Overall survival (mo)
MP
1	9.8	N/A	1	SD	7	656.6	0.15	N/A	1.00	63.1^*	63.1^*
2	13.3	N/A	1	SD	9	668.4	0.15	N/A	1.00	100.2^*	100.2^*
NB
3	9.2	NA	1	SD	13	444	0.15	NR	0.85	100.6^*	100.6^*
4	7.7	NA	0	SD	11	462.5	0.15	NR	1.00	79.2	99.0^*
5	9.9	NA	1	SD	8	673.2	0.15	NR	0.88	94.1^*	94.1^*
6	6.0	NA	2	PD	6	669.7	0^†	NR	1.00	6.5	15.5
7	2.0	Ampl	0	SD	2^‡	647.5	0.25	NR	1.00	91.8^*	91.8^*
8	2.8	NA	1	SD	20	677.1	0.25	NR	1.00	83.3^*	83.3^*
9	3.3	Ampl	2	PD	2^‡	662.3	0.25	PD	1.00	0.9	3.7
10	4.7	NA	0	SD	14	632.7	0.25	NR	1.00	71.8^*	71.8^*
11	5.8	NA	5	PD	2^‡	662.3	0.25	PD	1.00	0.7	4.8
12	6.1	Ampl	2	PD	21	691.9	0.25	PD	0.90	2.8	4.0
13	6.1	NA	4	PD	2^‡	677.1	0.25	PD	1.00	1.4	8.7
14	6.2	Ampl	3	SD	5	662.3	0.25	PD	1.00	6.5	14.4
15	7.8	NA	4	SD	13	636.4	0.25	NR	1.00	3.7	14.7
16	8.3	NA	3	SD	21	658.6	0.25	NR	0.95	3.6	8.8
17	8.4	NA	0	SD	9	684.5	0.25	NR	0.88	83.3^*	83.3^*
18	8.4	NA	1	PD	10	654.9	0.25	PD	1.30	1.2	27.2
19	8.7	NA	3	PD	6	688.2	0.25	PD	1.50	1.2	9.8
20	15.2	NA	1	SD	9	647.5	0.25	NR	1.00	6.2	23.7
21	30.4	NA	2	PD	8	658.6	0.25^{^§}	NR	0.63	11.5	61.6

↵* Continue to be progression-free.
↵† Arsenic trioxide not administered because of central-line–induced arrhythmia.
↵‡ MIBG–avid soft-tissue disease only.
↵§ Only 6 of 10 planned arsenic trioxide doses were administered because of diarrhea and electrolyte imbalance.
INRC = International Neuroblastoma Response Criteria; NB = neuroblastoma; N/A = not applicable; NA = not amplified; Ampl = amplified; SD = stable disease; PD = progressive disease; NR = no response.